Dr. Nowakowski, a Professor of Oncology and Medicine in the Division of Hematology at the Mayo Clinic, talks about the revolution in treatment options in diffuse large B-cell lymphoma(DLBCL).

"The last couple of years, we've seen quite a revolution in the treatment of DLBCL," he said. "We have multiple approved therapies now, and more coming, so it's really a very rapidly changing field."

He also discusses the five-year follow-up data from the L-MIND study, which evaluated tafasitamab in combination with lenalidomide.